康方生物(9926.HK)抗癌新藥AK117(CD47單克隆抗體)首例患者成功入組給藥
格隆匯5月14日丨2020年5月11日,康方生物(9926.HK)宣佈其旗下自主研發抗癌新藥AK117(CD47單克隆抗體)在澳洲的臨牀試驗中,首例患者已經順利入組和給藥。
CD47高表達於多種腫瘤細胞,通過與巨噬細胞表面的SIRPα結合釋放“別吃我”信號,抑制巨噬細胞的吞噬作用。靶向CD47藥物單藥和聯合治療在血液腫瘤和實體瘤中均顯示出良好的抗腫瘤療效,是下一代腫瘤免疫治療的熱門靶點。
康方董事長兼夏瑜博士表示:“2020年4月,AK117臨牀試驗IND獲得美國食品藥物管理局FDA批准,今天我們又迎來了AK117澳洲首例患者順利入組給藥的里程碑,我們欣然宣佈,康方自主研發的CD47單克隆抗體新藥AK117臨牀試驗進展順利。不僅豐富了康方生物在腫瘤免疫治療領域的產品佈局,也為未來康方生物抗癌管線的靈活開發鋪設了更加寬闊的道路。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.